SCHEMBL5034229

SCHEMBL5034229

COC(=O)CCCCCOCCO

nearest known ligand 0.54

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.54
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
GAA P10253 1/20 0.50
THRB P10828 1/20 0.50
HTT P42858 1/20 0.50
MAPT P10636 1/20 0.50
LMNA P02545 2/20 0.48
ALDH1A1 P00352 2/20 0.48
EPHX2 P34913 2/20 0.43
MAPK1 P28482 1/20 0.40
DGKA P23743 1/20 0.39
RECQL P46063 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6424609 0.98 TSHR (0.56) TSHRKMT2AMEN1GAATHRB
SCHEMBL19666673 0.92 TSHR (0.58) TSHRKMT2AMEN1GAATHRB
SCHEMBL16059320 0.92 TSHR (0.64) TSHRKMT2AMEN1GAALMNA
SCHEMBL8368795 0.92 TSHR (0.64) TSHRKMT2AMEN1GAALMNA
SCHEMBL25193436 0.92 TSHR (0.64) TSHRKMT2AMEN1GAALMNA
SCHEMBL25196628 0.92 TSHR (0.64) TSHRKMT2AMEN1GAALMNA
SCHEMBL8741176 0.90 TSHR (0.56) TSHRKMT2AMEN1GAATHRB
SCHEMBL29264633 0.90 TSHR (0.56) TSHRKMT2AMEN1GAATHRB
Di(Hydroxyethyl)Ether SCHEMBL3728453 0.88 TSHR (0.58) TSHRKMT2AMEN1GAATHRB
Tetraethylene Glycol SCHEMBL28172441 0.87 MAPT (0.60) TSHRKMT2AMEN1THRBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023193789-A1 WEE1 DEGRADING COMPOUNDS BEIJING NEOX BIOTECH LIMITED (CN) 2023-10-12 WO disclosed
CN-116829570-A WEE1 degrading compounds 北京星奇原生物科技有限公司 2023-09-29 CN disclosed
EP-1896086-A1 HYDRAZIDE CONJUGATES AS IMAGING AGENTS Bristol-Myers Squibb Pharma Company (US) 2008-03-12 EP disclosed
US-20070014721-A1 Hydrazide conjugates as imaging agents LANTHEUS MEDICAL IMAGING, INC. 2007-01-18 US disclosed
US-20070014721-A1 Hydrazide conjugates as imaging agents LANTHEUS MEDICAL IMAGING, INC. 2007-01-18 US disclosed
US-20070014721-A1 Hydrazide conjugates as imaging agents LANTHEUS MEDICAL IMAGING, INC. 2007-01-18 US disclosed
WO-2007005491-A1 HYDRAZIDE CONJUGATES AS IMAGING AGENTS BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2007-01-11 WO disclosed
WO-2007005491-A1 HYDRAZIDE CONJUGATES AS IMAGING AGENTS BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070014721-A1 Hydrazide conjugates as imaging agents CA14, CA13, CA1 TSHR 2921/4885KMT2A 2223/4885MEN1 1278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.